Novel insights into MSC-EVs therapy for immune diseases

Abstract Mesenchymal stromal cells (MSC) are a heterogeneous cell population with self-renewal and the ability to differentiate into different lineages. The novel regulatory role of MSC in both adaptive and innate immune responses got extensive investigation and MSC have been widely used in clinical...

Full description

Saved in:
Bibliographic Details
Main Authors: Peilong Lai (Author), Jianyu Weng (Author), Liyan Guo (Author), Xiaomei Chen (Author), Xin Du (Author)
Format: Book
Published: BMC, 2019-03-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_a1f848be29254faeada39db0ceb7a2db
042 |a dc 
100 1 0 |a Peilong Lai  |e author 
700 1 0 |a Jianyu Weng  |e author 
700 1 0 |a Liyan Guo  |e author 
700 1 0 |a Xiaomei Chen  |e author 
700 1 0 |a Xin Du  |e author 
245 0 0 |a Novel insights into MSC-EVs therapy for immune diseases 
260 |b BMC,   |c 2019-03-01T00:00:00Z. 
500 |a 10.1186/s40364-019-0156-0 
500 |a 2050-7771 
520 |a Abstract Mesenchymal stromal cells (MSC) are a heterogeneous cell population with self-renewal and the ability to differentiate into different lineages. The novel regulatory role of MSC in both adaptive and innate immune responses got extensive investigation and MSC have been widely used in clinical trials as immunosuppressive agents for autoimmune and inflammatory diseases, including graft-versus-host disease (GVHD), multiple sclerosis (MS), systemic lupus erythematosus (SLE), chronic kidney disease, etc. Recent studies have found that MSC exerted their immunomodulation function through secreting extracellular vesicles (EVs), which delivered parent cell cargo to recipient cells without oncogenicity or variability. Since MSC-EVs exhibit most of the properties of MSC and take advantage of their cellular immunomodulatory fuction, MSC-EVs appear to a promising none-cell therapy in various human diseases. In this review, we summarize the pivotal roles of MSC-EVs as agents for immunotherapy in diseases. 
546 |a EN 
690 |a Mesenchymal stromal cells 
690 |a Extracellular vesicles 
690 |a Immunomodulation 
690 |a Graft-versus-host disease 
690 |a Inflammatory diseases 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Biomarker Research, Vol 7, Iss 1, Pp 1-10 (2019) 
787 0 |n http://link.springer.com/article/10.1186/s40364-019-0156-0 
787 0 |n https://doaj.org/toc/2050-7771 
856 4 1 |u https://doaj.org/article/a1f848be29254faeada39db0ceb7a2db  |z Connect to this object online.